Skip to content

GDPoster

Aspirin may Hasten Progression of Cancers in Elderly Patients

    Aspirin may decrease the risk of developing cancer, according to the study conducted by a binational team led by researchers at Massachusetts General Hospital (MGH), the Berman Center in Minnesota, and Monash University in Australia. Compelling evidence from clinical trials that included predominantly middle-aged adults demonstrates that aspirin may reduce the risk of developing cancer,… Read More »Aspirin may Hasten Progression of Cancers in Elderly Patients

    Canakinumab Holds Potential In Treating Large Joint Osteoarthritis

      Patients receiving interleukin-1£] (IL-1£]) inhibitors had lower rates of total hip or total knee replacements over an average follow up of 3.7 years, according to an exploratory analysis of data from the CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study), which is a randomized double-blind, placebo-controlled trial. These findings are important, as no treatments currently exist that… Read More »Canakinumab Holds Potential In Treating Large Joint Osteoarthritis

      World Hepatitis Day

        Highlights: World Hepatitis Day is celebrated annually on 28th July to create awareness on the global burden of viral hepatitis Around 290 million people are living with viral hepatitis unaware worldwide The theme for 2020 is ‘Find The Missing Millions’. World Hepatitis Day is celebrated annually on July 28th.Organizations around the world celebrate World Hepatitis… Read More »World Hepatitis Day

        EMA Green Light for Avapritinib for GIST, Acalabrutinib for CLL

          The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a thumbs up to two new oncology drugs. The Committee has recommended granting conditional marketing authorization for avapritinib (Ayvakit, Blueprint Medicines) for use in adults with unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation,… Read More »EMA Green Light for Avapritinib for GIST, Acalabrutinib for CLL

          ‘Doc, Can I Get a Mask Exemption?’

            As more jurisdictions mandate facial coverings in public, questions have arisen about whether it’s safe for everyone — including those with lung disease — to wear masks. Stories about people who claim to be unable to wear masks because of breathing problems are appearing in the news with increasing frequency, and patients are starting to call their… Read More »‘Doc, Can I Get a Mask Exemption?’

            Russia 1st Nation to Successfully Finish Human Trials for Potential COVID-19 Vaccine

              As the world reels under the growing coronavirus cases, Russia’s Sechenov University has successfully completed the world’s first clinical trials of COVID-19 vaccine on humans. Chief researcher Elena Smolyarchuk, who heads the Center for Clinical Research on Medications at Sechenov University, told Russian news agency TASS on Sunday that the human trials for the vaccine… Read More »Russia 1st Nation to Successfully Finish Human Trials for Potential COVID-19 Vaccine

              Hydroxychloroquine, Lopinavir/Ritonavir Trial Discontinued for COVID-19 Treatment

                For its Solidarity Trial, the World Health Organization (WHO) has announced that it was discontinuing hydroxychloroquine and lopinavir/ritonavir, citing little or no reduction in the mortality of hospitalized COVID-19 patients. The WHO said the decision was in light of the evidence from the Solidarity Trial interim results. “These interim trial results show that hydroxychloroquine and… Read More »Hydroxychloroquine, Lopinavir/Ritonavir Trial Discontinued for COVID-19 Treatment